Compound 17 Inhibits Lung Cancer Progression via Inducing Cellular Apoptosis and Blocking TNF Signaling Pathway Activation
International Journal of Molecular Sciences · 2026
DOI: 10.3390/ijms27041693 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2026. Verfasst von Jiexin Zhang und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Apoptosis, Signal Transduction, Tumor Necrosis Factor-alpha. Die Arbeit nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ningxia Natural Science Foundation Project.
Abstract (Originalsprache)
Lung cancer ranks among the most commonly diagnosed malignancies worldwide, with dismal prognosis largely due to its intrinsic drug resistance and high recurrence rate. Herein, we synthesized 30 glycyrrhetinic acid derivatives and evaluated their anti-lung cancer potential both in vitro and in vivo. The biological effects of compound 17 on A549 cells were determined using MTT, colony formation, and Transwell assays. Flow cytometry, transcriptomic profiling, and RT-qPCR were performed to identify differentially expressed genes, followed by GO and KEGG enrichment analyses and molecular docking validation. A mouse xenograft tumor model was employed to assess therapeutic efficacy and systemic toxicity. Compound 17 exhibited dose-dependent inhibition of A549 cell proliferation, migration, and invasion, achieving an IC50 value of 0.6011 ± 0.05 μM. It induced G1-phase cell cycle arrest and apoptosis by inhibiting the TNF signaling pathway and modulating apoptosis-related proteins. In vivo experiments demonstrated that compound 17 exerted a tumor inhibition rate of 80.61% without observable toxic side effects. This study is the first to demonstrate that compound 17 exerts potent anti-lung cancer activity by targeting the TNF signaling pathway and activating the mitochondrial apoptosis pathway, providing a critical experimental foundation for its development as a novel therapeutic agent against lung cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chinese Medicinal Materials, Jilin Agricultural University, Changchun 130118, China.
- International Joint Laboratory for Development of Animal and Plant Resources for Food and Medicine, Jilin Agricultural University, Changchun 130118, China.
ORCID-Profile: Yan Zhao
Förderung
- Ningxia Natural Science Foundation Project
Zitieren
APA
Zhang, J., Zhang, Y., Zhao, Y., Shen, H., Zhao, Y., & Teng, H. (2026). Compound 17 Inhibits Lung Cancer Progression via Inducing Cellular Apoptosis and Blocking TNF Signaling Pathway Activation. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms27041693
Vancouver
Zhang J, Zhang Y, Zhao Y, Shen H, Zhao Y, Teng H. Compound 17 Inhibits Lung Cancer Progression via Inducing Cellular Apoptosis and Blocking TNF Signaling Pathway Activation. International Journal of Molecular Sciences. 2026. doi:10.3390/ijms27041693
BibTeX
@article{Zhang2026,
author = {Zhang, Jiexin and Zhang, Yunya and Zhao, Yaru and Shen, Huiyue and Zhao, Yan and Teng, Hongbo},
title = {Compound 17 Inhibits Lung Cancer Progression via Inducing Cellular Apoptosis and Blocking TNF Signaling Pathway Activation},
journal = {International Journal of Molecular Sciences},
year = {2026},
doi = {10.3390/ijms27041693}
}
EUVIMED